Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · IEX Real-Time Price · USD
1.671
-0.029 (-1.71%)
Jul 22, 2024, 11:15 AM EDT - Market open
Dermata Therapeutics Employees
Dermata Therapeutics had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,086,101
Market Cap
1.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 1 | 14.29% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Assure Holdings | 95 |
| China SXT Pharmaceuticals | 78 |
| LogicMark | 27 |
| Biodexa Pharmaceuticals | 21 |
| Seelos Therapeutics | 16 |
| Bluejay Diagnostics | 10 |
| SCWorx | 9 |
| GRI Bio | 4 |
DRMA News
- 5 days ago - Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Accesswire
- 2 months ago - Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results - Accesswire
- 4 months ago - Dermata to Present at the Emerging Growth Conference on April 3, 2024 - Accesswire
- 4 months ago - Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results - Accesswire
- 6 months ago - Dermata to Present at the Emerging Growth Conference on February 7, 2024 - Accesswire
- 7 months ago - Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis - Accesswire
- 7 months ago - Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Accesswire